1. Scrip

Sun Hopes Cequa’s Nano Formulation Makes Big Impact

 
• By Joseph Haas

Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes

Sun Pharmaceutical Industries Ltd. became the third company to gain US FDA approval of a drug for dry eye disease Aug. 16, as Cequa (cyclosporine ophthalmic solution 0.09%) was approved to increase tear production in patients suffering dry eye. At launch, expected to occur between October and next March, the drug will join Shire PLC’s Xiidra (lifitegrast) and Allergan PLC’s Restasis, also a cyclosporine A formulation, in the US dry eye market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip